Go Deep
Ovid Therapeutics Inc.
Ovid Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,653 | -10.0 | 2.04 | 0.06 | 208.56 |
| Oct 2026 | 19,653 | -10.0 | 2.04 | 0.06 | 207.94 |
| Oct 2026 | 19,507 | -10.3 | 2.10 | 0.06 | 214.61 |
| Oct 2026 | 19,736 | -9.8 | 2.00 | 0.06 | 203.64 |
| Oct 2026 | 19,695 | -9.9 | 2.02 | 0.06 | 205.75 |
| Oct 2026 | 19,299 | -10.7 | 2.20 | 0.06 | 223.77 |
| Oct 2026 | 19,071 | -11.2 | 2.30 | 0.06 | 233.62 |
| Oct 2026 | 19,279 | -10.8 | 2.21 | 0.06 | 223.71 |
Ovid Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 733,000.0 | 0.0 | 718,000.0 | 132,000.0 |
| Net Profit | -15,009,000.0 | -16,988,000.0 | 9,663,000.0 | -12,158,000.0 |
| EPS | -0.1 | -0.1 | 0.1 | -0.2 |
Ovid Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 7,252,000.0 | 566,000.0 | 392,000.0 | 1,502,748.0 | — |
| Net Profit | -17,414,000.0 | -26,433,000.0 | -52,339,000.0 | -54,169,029.0 | — |
| EPS | -0.2 | -0.4 | -0.7 | -0.8 | — |
Ovid Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 150,934,000.0 | 92,167,000.0 | 144,027,000.0 | 155,265,814.0 | — |
| Total Liabilities | 20,274,000.0 | 23,941,000.0 | 56,229,000.0 | 22,993,250.0 | — |
| Total Equity | 130,660,000.0 | 68,226,000.0 | 87,798,000.0 | 132,272,564.0 | — |
Owes vs Owns
Ovid Therapeutics Inc. owed $0.10 for every $1 it owned in Jun 2026, down from $0.15 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.10× | 0.13× | 0.26× | 0.39× | 0.15× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Ovid Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 46.1%Fixed assets (tangible) 7.9%Long-term investments 41.6%Other assets 4.4%
How it's funded — Dec 2025
Short-term debt 0.9%Long-term debt 7.9%Payables 1.3%Other liabilities 3.2%Shareholders' equity 86.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 69.6 | 53.1 | 105.8 | 129.0 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 11.9 | 13.2 | 14.7 | 16.1 |
| Intangible assets | 0.0 | 0.0 | 0.2 | 0.2 |
| Long-term investments | 62.8 | 21.0 | 17.6 | 5.6 |
| Other assets | 6.7 | 4.9 | 5.7 | 4.3 |
| Liabilities & equity | ||||
| Short-term debt | 1.4 | 1.3 | 1.2 | 0.5 |
| Long-term debt | 12.0 | 13.4 | 14.8 | 16.0 |
| Payables | 2.0 | 3.2 | 3.7 | 2.0 |
| Other liabilities | 4.9 | 6.0 | 36.5 | 4.5 |
| Shareholders' equity | 130.7 | 68.2 | 87.8 | 132.3 |
| Net tangible assets | 130.7 | 68.2 | 87.8 | 132.1 |
Ovid Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -38,334,000.0 | -55,956,000.0 | -45,781,000.0 | -55,227,127.0 | — |
| Investing Activities | -49,854,000.0 | 54,594,000.0 | -2,581,000.0 | -87,883,217.0 | — |
| Financing Activities | 75,207,000.0 | 622,000.0 | 30,535,000.0 | 180,658.0 | — |